Biologic basis of osteoarthritis: State of the evidence

Current Opinion in Rheumatology

Volumn 27, Issue 3, 2015, Pages 289-294

  Malemud, Charles J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A disintegrin and metalloproteinase with thrombospondin motif; Adipokines; Cytokines; Innate and adaptive immunity; Matrix metalloproteinases

Indexed keywords

ACUTE PHASE PROTEIN; COMPLEMENT; DISINTEGRIN; MATRIX METALLOPROTEINASE; THROMBOSPONDIN; AUTACOID;

B LYMPHOCYTE; BONE DESTRUCTION; CARTILAGE CELL; CARTILAGE DEGENERATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL CULTURE; INFLAMMATION; MACROPHAGE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SYNOVIAL FLUID; SYNOVITIS; SYNOVIUM; T LYMPHOCYTE; METABOLISM;

HUMANS; INFLAMMATION MEDIATORS; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 84926303946     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000162     Document Type: Review

References (75)

1. Hügle T, Geurts J, Nüesch C, et al. Aging and osteoarthritis: An inevitable encounter? J Aging Res 2012; 2012:950192.
2. Pelletier J-P, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implications for the selection of new therapeutic targets. Arthritis Rheum 2001; 44:1237-1247.
3. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010; 6:625-635.
4. Mueller MB, Tuan RS. Anabolic/catabolic balance in the pathogenesis of osteoarthritis: identifying molecular targets. PMR 2011; 3 (6 Suppl 1):S3-S11.
5. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23:471-478.
6. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone 2012; 51:249-257.
7. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013; 21:16-21.
8. Cicuttini FM, Wluka AE. Osteoarthritis: is OA a mechanical or systemic disease? Nat Rev Rheumatol 2014; 10:515-516.
9. Wang X, Hunter D, Xu J, et al. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage 2015; 23:22-30.
10. Sakkas LI, Platsoucas CD. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum 2007; 56:409-424.
11. de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: A review. Osteoarthritis Cartilage 2012; 20:1484-1499.
12. Haseeb A, Haqqi TM. Immunopathogenesis of osteoarthritis. Clin Immunol 2013; 146:185-196.
13. Meszaros E, Malemud CJ. Prospects for treating osteoarthritis: Enzyme-protein interactions regulating matrix metalloproteinase activity. Therapeut Adv Chronic Dis 2012; 3:219-229.
14. Malemud CJ. Regulation of chondrocyte matrix metalloproteinase gene expression. In: Dhalla NS, Chakraborti S, editors. Role of proteases in cellular dysfunction. United Kingdom: Springer Science; 2013. pp. 63-77.
15. Gargiulo S, Gamba P, Poli G, et al. Metalloproteinases and metalloproteinase inhibitors in age-related diseases. Curr Pharm Des 2014; 20:2993-3018.
16. Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem 2011; 112:3507-3514.
17. Zhang E, Yan X, Zhang M, et al. Aggrecanases in the human synovial fluid at different stages of osteoarthritis. Clin Rheumatol 2013; 32:797-803.
18. Sylvester J, El Mabrouk M, Ahmad R, et al. Interleukin-1 induction of aggrecanase gene expression in human articular chondrocytes is mediated by mitogen-activated protein kinases. Cell Physiol Biochem 2012; 30:563-574.
19. Xue J, Wang J, Liu Q, et al. Tumor necrosis factor-a induces ADAMTS-4 expression in human osteoarthritis chondrocytes. Mol Med Rep 2013; 8:1755-1760.
20. Wu L, Huang X, Li L, et al. Insights on biology and pathology of HIF-1a/-2a, TGFb/BMP, Wnt/b-catenin and NF-kB pathways in osteoarthritis. Curr Pharm Des 2012; 18:3293-3312.
21. Melas IN, Chairakaki AD, Chatzopoulou EI, et al. Modeling of signaling pathways in chondrocytes based on phosphoproteomics and cytokine release data. Osteoarthritis Cartilage 2014; 22:509-518.
22. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7:33-42.
23. Jiang Y, Xiao Q, Hu Z, et al. Tissue levels of leukemia inhibitory factor vary by osteoarthritis grade. Orthopedics 2014; 37:e460-e464.
24. Funck-Brentano T, Cohen-Solal M. Crosstalk between cartilage and bone: when bone cytokines matter. Cytokine Growth Factor Rev 2011; 22:91-97.
25. Wang M, Shen J, Jin H, et al. Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis. Ann N Y Acad Sci 2011; 1240:61-69.
26. Li H, Li L, Min J, et al. Levels of metalloproteinase (MMP-3, MMP-9), NF-kappaB ligand (RANKL), and nitric oxide (NO) in peripheral blood of osteoarthritis (OA) patients. Clin Lab 2012; 58:755-762.
27. Leijten JC, Bos SD, Landman EB, et al. GREM1, FRZB and DKK1 mRNA levels correlate with osteoarthritis and are regulated by osteoarthritis-related factors. Arthritis Res Ther 2013; 15:R126.
28. Rigoglou S, Papavassiliou AG. The NF-kB signalling pathway in osteoarthritis. Int J Biochem Cell Biol 2013; 45:2580-2584.
29. Houard X, Goldring MB, Berenbaum F. Homeostatic mechanisms in articular cartilage and role of inflammation in osteoarthritis. Curr Rheumatol Rep 2013; 15:375.
30. Sun R, Zhang B, Chen L, et al. Role of nuclear factor of activated T cells in the pathogenesis of osteoarthritis. Exp Ther Med 2014; 7:195-198.
31. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: The cytokine connection. Cytokine 2014; 70:185-193.
32. Bevill SL, Boyer KA, Andriacchi TP. The regional sensitivity of chondrocyte gene expression to coactive mechanical load and exogenous TNF-a stimuli. J Biomech Eng 2014; 136:091005.
33. Hermann J, Lipp RW, Dunzinger A, et al. Anti-TNF scintigraphy to assess TNFa-associated joint inflammation in rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol 2014; 32:614.
34. Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm 2014; 2014:561459.
35. Blasioli DJ, Kaplan DL. The roles of catabolic factors in the development of osteoarthritis. Tissue Eng Part B Rev 2014; 20:355-363.
36. Remst DF, Blom AB, Vitters EL, et al. Gene expression analysis of murine and human osteoarthritis synovium reveals expression of transforming growth factor b-responsive genes in osteoarthritis-related fibrosis. Arthritis Rheumatol 2014; 66:647-656.
37. Muoh O, Malemud CJ, Askari AD. Clinical significance and implications of genetic and genomic studies in patients with osteoarthritis. Adv Genomics Genet 2014; 4:193-206.
38. Ratnayake M, Ploger F, Santibanez-Koref M, et al. Human chondrocytes respond discordantly to the protein encoded by the osteoarthritis susceptibility gene GDF5. PLoS One 2014; 9:e86590.
39. Kokebie R, Aggarwal R, Lidder S, et al. The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. Arthritis Res Ther 2011; 13:R50.
40. Livshits G, Zhai G, Hart DJ, et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: The Chingford study. Arthritis Rheum 2009; 60:2037-2045.
41. Moktar NM, Yusof HM, Yahaya NH, et al. The transcript level of interleukin-6 in the cartilage of idiopathic osteoarthritis of knee. Clin Ter 2010; 161: 25-28.
42. Stannus O, Jones G, Cicuttini F, et al. Circulating levels of IL-6 and TNF-a are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthritis Cartilage 2010; 18:1441-1447.
43. Orita S, Koshi T, Mitsuka T, et al. Associations between proinflammatory cytokines in the synovial fluid and radiographic grading and pain-related scores in 47 consecutive patients with osteoarthritis of the knee. BMC Musculoskelet Disord 2011; 12:144.
44. Abe H, Sakai T, Ando W, et al. Synovial joint fluid cytokine levels in hip disease. Rheumatology (Oxford) 2014; 53:165-172.
45. Barker T, Rogers VE, Henriksen VT, et al. Serum cytokines are increased and circulating micronutrients are not altered in subjects with early compared to advanced knee osteoarthritis. Cytokine 2014; 68:133-136.
46. Chen B, Deng Y, Tan Y, et al. Association between severity of knee osteoarthritis and serum and synovial fluid interleukin 17 concentrations. J Int Med Res 2014; 42:138-144.
47. Vangsness CT Jr, Burke WS, Narvy SJ, et al. Human knee synovial fluid cytokines with grade of knee osteoarthritis: A pilot study. Bull NYU Hosp Jt Dis 2011; 69:122-127.
48. Liu M, Hu C. Association of MIF in serum and synovial fluid with severity of osteoarthritis. Clin Biochem 2012; 45:737-739.
49. Malemud CJ. Anticytokine therapy for osteoarthritis: Evidence to date. Drugs Aging 2010; 27:95-115.
50. McNulty AL, Rothfusz NE, Leddy HA, Guilak F. Synovial fluid concentrations and relative potency of interleukin-1 alpha and beta in cartilage and meniscus degeneration. J Orthop Res 2013; 31:1039-1045.
51. Tsuchida AI, Beekhuizen MT, Hart MC, et al. Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes. Arthritis Res Ther 2014; 16:441.
52. Lago R, Gomez R, Otero M, et al. A new player in cartilage homeostasis: Adiponectin induces nitric oxide synthase II and pro-inflammatory cytokines in chondrocytes. Osteoarthritis Cartilage 2008; 16:1101-1109.
53. Kang EH, Lee YJ, Kim TK, et al. Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res Ther 2010; 12:R231.
54. de Boer TN, van Spil WE,Huisman AM, et al. Serumadipokines in osteoarthritis: Comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. Osteoarthritis Cartilage 2012; 20:846-853.
55. Koskinen A, Vuolteenaho K, Moilanen T, et al. Resistin as a factor in osteoarthritis: Synovial fluid resistin concentrations correlate positively with interleukin 6 and matrix metalloproteinases MMP-1 and MMP-3. Scand J Rheumatol 2014; 43:249-253.
56. Jiang L, Bao J, Zhou X, et al. Increased serum levels and chondrocyte expression of nesfatin-1 in patients with osteoarthritis and its relation with BMI, hsCRP and IL-18. Mediators Inflamm 2013; 2013:631251.
57. Laiguillon MC, Huard X, Bougault C, et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways in osteoarthritis. Arthritis Res Ther 2014; 16:R38.
58. Yang S, Ryu JH, Oh H, et al. NAMPT (visfatin), a direct target of hypoxiainducible factor-2a, is an essential catabolic regulator of osteoarthritis. Ann Rheum Dis 2015; 74:595-602.
59. Malemud CJ, Schulte ME. Is there a final common pathway for arthritis? Future Rheumatol 2008; 3:253-268.
60. Chevalier X, Goupille P, Beaulieu AD, et al. Intrarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2009; 61:344-352.
61. Jotanovic Z, Mihelic R, Sestan B, et al. Role of interleukin-1 inhibitors in osteoarthritis: An evidence-based review. Drugs Aging 2012; 29:343-358.
62. Fu Z, Liu P, Yang D, et al. Interleukin-18-induced inflammatory responses in synoviocytes and chondrocytes from osteoarthritic patients. Int J Mol Med 2012; 30:805-810.
63. Beekhuizen H, van Osch GJ, Bot AG, et al. Inhibition of oncostatin M in osteoarthritic synovial fluid enhances GAG production in osteoarthritic cartilage repair. Eur Cell Mater 2013; 26:80-90.
64. Tu G, Xu W, Huang H, et al. Progress in the development of matrix metalloproteinase inhibitors. Curr Med Chem 2008; 15:1388-1395.
65. Krzeski P, Buckland-Wright C, Bá lint G, et al. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: A randomized, 12-month, double-blind, placebo-controlled trial. Arthritis Res Ther 2007; 9:R109.
66. Flannery CR. Novel therapies in OA. Curr Drug Targets 2010; 11:614-619.
67. WuL, Liu H, Li L, et al. Mitochondrial pathology in osteoarthritic chondrocytes. Curr Drug Targets 2014; 15:710-719.
68. Zhou M, Qin S, Chu Y, et al. Immunolocalization of MMP-2 and MMP-9 in human rheumatoid synovium. Int J Clin Exp Pathol 2014; 7:3048-3056.
69. Bondeson J. Activated synovial macrophages as targets for osteoarthritis drug therapy. Curr Drug Targets 2010; 11:576-585.
70. Wassilew GI, Lehnigk U, Duda GN, et al. The expression of proinflammatory cytokines and matrix metalloproteinases in the synovial membranes of patients with osteoarthritis compared with traumatic knee disorders. Arthroscopy 2010; 26:1096-1104.
71. Alcaraz MJ, Megias J, Garcia-Arnandis I, et al. New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol 2010; 80:13-21.
72. Bondeson J. Are we moving in the right direction with osteoarthritis drug discovery? Expert Opin Ther Targets 2011; 15:1355-1368.
73. Chevalier X, Conrozier T, Richette P. Desperately looking for the right target in osteoarthritis: The anti-IL-1 strategy. Arthritis Res Ther 2011; 13:124.
74. Mobasheri A. The future of osteoarthritis therapeutics: Emerging biological therapy. Curr Rheumatol Rep 2013; 15:385.
75. Chevalier X, Eymard F, Richette P. Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol 2013; 9:400-410.